Literature DB >> 17064638

Recent insights into the mechanisms of antifungal resistance.

Katherine S Barker1, P David Rogers.   

Abstract

The incidence of fungal infections has increased in recent years, particularly among immunocompromised individuals. Treatment of invasive fungal infections has been hampered by a limited number of available antifungal agents and both intrinsic and acquired resistance to these agents among many fungal pathogens. Therefore, much interest has focused on elucidating the molecular basis for antifungal resistance. Recent efforts have increased our understanding of this process, including the transcriptional regulation of azole resistance in Candida spp, mechanisms of intrinsic resistance to amphotericin B, and mechanisms of acquired resistance to the new echinocandin class of antifungal agents. This review discusses these and other newly clarified resistance mechanisms, as well as the direction of future antifungal resistance research. Despite these advances, undiscovered resistance determinants exist, and resistance to newer agents likely will continue to emerge.

Entities:  

Year:  2006        PMID: 17064638     DOI: 10.1007/s11908-006-0019-3

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.663


  46 in total

1.  Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome.

Authors:  L J Wheat; P Connolly; M Smedema; E Brizendine; R Hafner
Journal:  Clin Infect Dis       Date:  2001-10-23       Impact factor: 9.079

Review 2.  Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions.

Authors:  A Vermes; H J Guchelaar; J Dankert
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

3.  TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2.

Authors:  Alix T Coste; Mahir Karababa; Françoise Ischer; Jacques Bille; Dominique Sanglard
Journal:  Eukaryot Cell       Date:  2004-12

4.  The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents.

Authors:  D Sanglard; F Ischer; D Calabrese; P A Majcherczyk; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Authors:  S Park; R Kelly; J Nielsen Kahn; J Robles; M-J Hsu; E Register; W Li; V Vyas; H Fan; G Abruzzo; A Flattery; C Gill; G Chrebet; S A Parent; M Kurtz; H Teppler; C M Douglas; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  A common drug-responsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistance.

Authors:  Michelle de Micheli; Jacques Bille; Christoph Schueller; Dominique Sanglard
Journal:  Mol Microbiol       Date:  2002-03       Impact factor: 3.501

7.  A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans.

Authors:  Alix Coste; Vincent Turner; Françoise Ischer; Joachim Morschhäuser; Anja Forche; Anna Selmecki; Judith Berman; Jacques Bille; Dominique Sanglard
Journal:  Genetics       Date:  2006-02-01       Impact factor: 4.562

8.  Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation.

Authors:  Spencer W Redding; William R Kirkpatrick; Stephen Saville; Brent J Coco; William White; Annette Fothergill; Michael Rinaldi; Tony Eng; Thomas F Patterson; Jose Lopez-Ribot
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

9.  Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.

Authors:  John E Bennett; Koichi Izumikawa; Kieren A Marr
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection.

Authors:  M Ruhnke; A Eigler; I Tennagen; B Geiseler; E Engelmann; M Trautmann
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

View more
  21 in total

1.  Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinically important yeast species.

Authors:  Lindsay G Stevenson; Steven K Drake; Yvonne R Shea; Adrian M Zelazny; Patrick R Murray
Journal:  J Clin Microbiol       Date:  2010-07-28       Impact factor: 5.948

2.  Inhibition of fungal and bacterial plant pathogens in vitro and in planta with ultrashort cationic lipopeptides.

Authors:  Arik Makovitzki; Ada Viterbo; Yariv Brotman; Ilan Chet; Yechiel Shai
Journal:  Appl Environ Microbiol       Date:  2007-08-24       Impact factor: 4.792

3.  Functional analysis of cis- and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system.

Authors:  Alix T Coste; Jérôme Crittin; Christopher Bauser; Bettina Rohde; Dominique Sanglard
Journal:  Eukaryot Cell       Date:  2009-06-26

4.  Ultraviolet-C light for treatment of Candida albicans burn infection in mice.

Authors:  Tianhong Dai; Gitika B Kharkwal; Jie Zhao; Tyler G St Denis; Qiuhe Wu; Yumin Xia; Liyi Huang; Sulbha K Sharma; Christophe d'Enfert; Michael R Hamblin
Journal:  Photochem Photobiol       Date:  2011-02-10       Impact factor: 3.421

Review 5.  Targeting the fungal cell wall: current therapies and implications for development of alternative antifungal agents.

Authors:  Sahar Hasim; Jeffrey J Coleman
Journal:  Future Med Chem       Date:  2019-04-17       Impact factor: 3.808

6.  Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi.

Authors:  C Borelli; M Schaller; M Niewerth; K Nocker; B Baasner; D Berg; R Tiemann; K Tietjen; B Fugmann; S Lang-Fugmann; H C Korting
Journal:  Chemotherapy       Date:  2008-06-30       Impact factor: 2.544

7.  Antifungal activity of four honeys of different types from Algeria against pathogenic yeast: Candida albicans and Rhodotorula sp.

Authors:  Ahmed Moussa; Djebli Noureddine; Aissat Saad; Meslem Abdelmelek; Benhalima Abdelkader
Journal:  Asian Pac J Trop Biomed       Date:  2012-07

8.  Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates.

Authors:  Alix Coste; Anna Selmecki; Anja Forche; Dorothée Diogo; Marie-Elisabeth Bougnoux; Christophe d'Enfert; Judith Berman; Dominique Sanglard
Journal:  Eukaryot Cell       Date:  2007-08-10

9.  Identification and functional characterization of Rca1, a transcription factor involved in both antifungal susceptibility and host response in Candida albicans.

Authors:  Patrick Vandeputte; Sylvain Pradervand; Françoise Ischer; Alix T Coste; Sélène Ferrari; Keith Harshman; Dominique Sanglard
Journal:  Eukaryot Cell       Date:  2012-05-11

10.  Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.

Authors:  Martine Florent; Thierry Noël; Gwenaël Ruprich-Robert; Bruno Da Silva; Valérie Fitton-Ouhabi; Christiane Chastin; Nicolas Papon; Florence Chapeland-Leclerc
Journal:  Antimicrob Agents Chemother       Date:  2009-05-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.